Active, not recruitingPhase 2NCT01627041
Decitabine, Cytarabine, and Daunorubicin Hydrochloride in Treating Patients With Acute Myeloid Leukemia
Studying Acute basophilic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- National Cancer Institute (NCI)
- Principal Investigator
- Joseph M Scandura, MDWeill Medical College of Cornell University
- Intervention
- Cytarabine(drug)
- Enrollment
- 178 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2011 – 2027
Study locations (9)
- Lafayette Family Cancer Center-EMMC, Brewer, Maine, United States
- Roswell Park Cancer Institute, Buffalo, New York, United States
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center, New York, New York, United States
- Memorial Sloan Kettering Cancer Center, New York, New York, United States
- NYP/Weill Cornell Medical Center, New York, New York, United States
- Montefiore Medical Center-Weiler Hospital, The Bronx, New York, United States
- Montefiore Medical Center - Moses Campus, The Bronx, New York, United States
- Case Western Reserve University, Cleveland, Ohio, United States
- Ohio State University Comprehensive Cancer Center, Columbus, Ohio, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT01627041 on ClinicalTrials.govOther trials for Acute basophilic leukemia
Additional recruiting or active studies for the same condition.